R&D News | pharmaphorum

News

ASCO: Moderna, Merck melanoma vaccine set for phase 3

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase

News

Biogen pulls the plug on late-stage Parkinson’s trial

Biogen has scaled back its ambitions for Denali-partnered Parkinson’s disease candidate BIIB122, abandoning a complex and likely costly phase 3 trial that isn’t due to com

News

ASCO: TIGIT returns with Roche, Gilead data

A year ago, enthusiasm for a new generation of cancer immunotherapies targeting TIGIT started to wane, after Roche’s tiragolumab was hit by two

News

ASCO: Vorasidenib shows its glioma potential in INDIGO

Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t

News

ASCO: AZ gets a practice-changing win in lung cancer

The question of whether adjuvant treatment with AstraZeneca’s Tagrisso can help patients with EGFR-positive non-small cell lung cancer live longer has finally been answere

News

ASCO: Can Imfinzi bring immunotherapy to ovarian cancer?

While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change

ASCO: Moderna, Merck melanoma vaccine set for phase 3

Biogen pulls the plug on late-stage Parkinson’s trial

ASCO: TIGIT returns with Roche, Gilead data

ASCO: Vorasidenib shows its glioma potential in INDIGO

ASCO: AZ gets a practice-changing win in lung cancer

ASCO: Can Imfinzi bring immunotherapy to ovarian cancer?

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks